Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:collaboratesWith |
gptkb:Eli_Lilly_and_Company
gptkb:Adimab |
| gptkbp:country |
gptkb:China
|
| gptkbp:focus |
biosimilars
immuno-oncology monoclonal antibodies |
| gptkbp:founded |
2011
|
| gptkbp:founder |
gptkb:Michael_Yu
|
| gptkbp:headquarters_location |
gptkb:Suzhou
|
| https://www.w3.org/2000/01/rdf-schema#label |
Suzhou Innovent Biologics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:IBI-305
gptkb:IBI-306 gptkb:Sintilimab |
| gptkbp:numberOfEmployees |
over 4000
|
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:01801.HK
|
| gptkbp:website |
https://www.innoventbio.com/
|
| gptkbp:bfsParent |
gptkb:Zhangjiang
|
| gptkbp:bfsLayer |
6
|